Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431444 · ClinicalTrials.gov registry record · Phase 4
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
A Phase 4 study of Osteoporosis, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
- 17
- Study locations
NCT00431444 is a Phase 4 study of Osteoporosis that has completed, run by Novartis. The registered enrollment target is 110 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (93% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT00431444, a Phase 4 study of Osteoporosis, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
Conditions Studied
Interventions
- DRUG Zoledronic acid
- DRUG Raloxifene
- DRUG Placebo oral pills
- DRUG Placebo intravenous (i.v.) infusion
Study Locations (17)
Florida
- Jacksonville Center for Clinical Research - Jacksonville
- Women's Physicians of Jacksonville - Jacksonville
- Tampa Clinical Research - Tampa
Oregon
- The Portland Clinic - Portland
- Oregon Health and Science University - Portland
Arizona
- Women's Health Research - Phoenix
California
- Associated Pharma Research Center - Buena Park
District of Columbia
- - Washington D.C.
Illinois
- Springfield Clinic - Springfield
Missouri
- Consultants in Women's Health Care - St Louis
Nebraska
- Alegent Health - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00431444
The ClinicalTrials.gov registry entry for NCT00431444 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (93% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 4 interventions - of which Zoledronic acid is the first listed.
NCT00431444 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Florida, Oregon, Arizona.
Frequently Asked Questions
What is clinical trial NCT00431444 about?
NCT00431444 is a clinical study titled "Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density". This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
What is the current status of trial NCT00431444?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2007-01. Estimated completion is 2008-07.
What conditions does trial NCT00431444 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00431444?
The interventions under investigation include: Zoledronic acid (DRUG), Raloxifene (DRUG), Placebo oral pills (DRUG), Placebo intravenous (i.v.) infusion (DRUG).
Who is sponsoring clinical trial NCT00431444?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00431444 being conducted?
This trial has 17 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.